Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Lynparza – API Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Lynparza – API Insight, 2019…
Myriad Genetics, AstraZeneca, and Merck have expanded their companion diagnostic collaboration, to use BRACAnalysis CDx to identify germline BRCA mutations in…
AstraZeneca and Merck’s work on Lynparza is looking at mroe financial return after the US Food and Drug Administration (FDA) approved it for for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer.
AstraZeneca and Merck’s Phase III SOLO-1 trial of Lynparza (olaparib) tablets, for women with BRCA-mutated (BRCAm) advanced ovarian cancer treated…
AstraZeneca and Merck have announced that the Japanese Ministry of Health, Labour and Welfare has approved Lynparza (olaparib) tablets (300mg…
AstraZeneca and Merck said Wednesday that th eUS Food and Drug Administration (FDA) has accepted and granted priority review for a…
AstraZeneca’s and Merck’s Lynparza new tablet’s formulation has been approved as maintenance treatment for women with platinum-sensitive recurrent ovarian cancer regardless of BRCA-mutation status, the companies said Friday.
AstraZeneca’s trial treating relapsed ovarian cancer patients with olaparib met its primary endpoint, the company said Tuesday.
AstraZeneca has announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations.
AstraZeneca’s Lynparza tablets against BRCA-mutated ovarian cancer have shown…